AquaBounty Applied sciences Inc. AQB skilled explosive after-hours buying and selling on Wednesday, with shares leaping 98.25% to $2.26 after closing at $1.14 throughout common buying and selling hours.
Take a look at the present value of AQB inventory right here.
NASDAQ Compliance Milestone Drives Rally
The biotech firm’s vital after-hours leap got here after it was confirmed that it met NASDAQ’s minimal bid value requirement. A Securities and Alternate Fee Type 8-Ok filed on Wednesday revealed that AquaBounty had obtained official affirmation from NASDAQ’s Itemizing {Qualifications} Division that the delisting situation had been resolved.
Delisting Threat Resolved
The corporate beforehand confronted delisting threat when its inventory value fell under $1.00 per share for 30 consecutive enterprise days, triggering a compliance violation in January.
See Additionally: BlackRock-Backed Minute Media Buys $250M Indian AI Startup That Turns Sports activities Into Immediate Viral Content material
Interim CEO David A. Frank signed the compliance notification submitting for the Massachusetts-based firm.
Technical Buying and selling Metrics Sign Volatility
AquaBounty’s inventory has gained 80.95% up to now in 2025. On September 4th, it peaked at $1.28 with a quantity of two.1 million shares. Yesterday, it closed at $1.14 with a considerably larger quantity of 14 million shares, exhibiting a lower of about 10.94% from its peak.
With a market capitalization of $4.42 million and common day by day quantity of 4.24 million shares, AquaBounty has a 52-week vary of $0.47-$1.62.
Value Motion: Based on Benzinga Professional knowledge, AQB’s common session efficiency confirmed modest good points of 0.88% on Wednesday.
Benzinga’s Edge Inventory Rankings spotlight that AQB has a Momentum rating of 83.97. Monitor the efficiency of different gamers on this section.
Learn Subsequent:
Picture Courtesy: Miha Inventive on Shutterstock.com
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
